Effects of phenoxybenzamine on the narcotic withdrawal syndrome in the rat.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008297:Male; D009021:Morphine Dependence; D009270:Naloxone / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D011398:Promethazine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D010643:Phenoxybenzamine; D009270:Naloxone; D011433:Propranolol; D011398:Promethazine; D010424:Pentobarbital; D006220:Haloperidol; D002746:Chlorpromazine; D010646:Phentolamine